Viracta Therapeutics Inc

NASDAQ:VIRXUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.

Contact Information

Headquarters

2533 S COAST HWY 101, SUITE 210CARDIFF BY THE SEA, CA, United States 92007

Phone

858-400-8470

Fax

650-266-3501

Executives

Independent Chairman of the Board

Roger Pomerantz

President, Chief Executive Officer, Director

Mark Rothera

Chief Financial Officer

Michael Faerm

Interim Principal Financial Officer and Interim Principal Accounting Officer

Melody Burcar

Chief Medical Officer

Darrel Cohen